Pliant Therapeutics Inc 2025年季度报告

SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember30, 2025☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromtoCommission File Number:001-39303 PLIANT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) 47-4272481(I.R.S. EmployerIdentification No.)94080(Zip Code) Delaware(State or other jurisdiction ofincorporation or organization)331 Oyster Point Blvd.,South San Francisco,CA(Address of principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒As of November1, 2025, the registrant had61,449,385shares of common stock, $0.0001 par value per share, outstanding. Table of Contents Condensed Financial Statements(Unaudited)Condensed Balance Sheets (Unaudited)Condensed Statements of Operations and Comprehensive Loss (Unaudited)Condensed Statements of Stockholders’ Equity (Unaudited)Condensed Statements of Cash Flows (Unaudited)Notes to Condensed Financial Statements (Unaudited)Management’s Discussion and Analysis of Financial Condition and Results of OperationsQuantitative and Qualitative Disclosures About Market RiskControls and Procedures Legal ProceedingsRisk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresOther InformationExhibits SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or this Report, contains forward-looking statements that involve risks, uncertainties, and assumptions that,if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-lookingstatements. The statements contained in this Report that are not purely historical are forward-looking statements within the meaning of Section 27A ofthe Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the ExchangeAct. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “could,” “estimate,”“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressionsthat convey uncertainty of future events or outcomes. Any statements contained herein that are not statements of historical facts may be deemed to beforward-looking statements. Forward-looking statements in this Report include, but are not limited to, statements about: •Our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;•The success, cost and timing of our product development activities and preclinical and clinical trials of our product candidates;•Our plans to initiate, recruit and enroll patients in, and conduct our clinical trials at the pace that we project;•Our plans and strategy to obtain and maintain regulatory approvals of our product candidates;•Our plans and strategy to obtain funding for our operations, including funding necessary to complete further development and, uponsuccessful development, if approved, commercialize any of our product candidates;•The effect and impact of new, existing and proposed laws and regulations;•The potential benefit of orphan drug and Fast Track designations for any of our product candidates;•Our ability to compete with companies currently marketing or engaged in the develop